FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122691108> ?p ?o ?g. }

• W2122691108 endingPage "1105" @default.
• W2122691108 startingPage "1097" @default.
• W2122691108 abstract "Purpose To identify risk factors for poor adherence to topical once daily therapy for glaucoma. Design Prospective, observational cohort study. Participants A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Methods Demographics, ocular history, and responses to interview questions about glaucoma knowledge, health beliefs, and drop-taking behaviors were obtained from each patient. All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc., Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months, and the data of drop use were downloaded using software provided with the DA. Patients taking ≤75% doses during the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit were compared with those taking >75% of doses. Main Outcome Measures Risk factors for poor adherence. Results Eighty-seven patients (44.4% of the 196 subjects with evaluable data at 3 months) used the DA on 75% or less of the monitored days. In univariate analysis, poorer adherers were more likely to be <50 or ≥80 years of age, to be African American, to report less than excellent health, to report higher amounts of depression, to have lower income, and to be treated at the Scheie Eye Institute. Multivariate analysis (adjusting for education and income) found that age, race/ethnicity, and less than excellent health were associated with poor adherence. Conclusions Those who failed to take more than 75% of eyedrop doses were more likely to be African American and to report poor health. Those in the youngest and oldest age groups were less adherent, although this finding was not always statistically significant. Further research into the factors driving these associations and into developing predictive models to assist in screening for low adherence are warranted. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. To identify risk factors for poor adherence to topical once daily therapy for glaucoma. Prospective, observational cohort study. A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007. Demographics, ocular history, and responses to interview questions about glaucoma knowledge, health beliefs, and drop-taking behaviors were obtained from each patient. All patients used the Travatan Dosing Aid (DA; Alcon Laboratories Inc., Fort Worth, TX) to administer travoprost as prescribed. Devices were collected at 3 months, and the data of drop use were downloaded using software provided with the DA. Patients taking ≤75% doses during the 8-week period starting 2 weeks after the enrollment visit and ending 2 weeks before the 3-month visit were compared with those taking >75% of doses. Risk factors for poor adherence. Eighty-seven patients (44.4% of the 196 subjects with evaluable data at 3 months) used the DA on 75% or less of the monitored days. In univariate analysis, poorer adherers were more likely to be <50 or ≥80 years of age, to be African American, to report less than excellent health, to report higher amounts of depression, to have lower income, and to be treated at the Scheie Eye Institute. Multivariate analysis (adjusting for education and income) found that age, race/ethnicity, and less than excellent health were associated with poor adherence. Those who failed to take more than 75% of eyedrop doses were more likely to be African American and to report poor health. Those in the youngest and oldest age groups were less adherent, although this finding was not always statistically significant. Further research into the factors driving these associations and into developing predictive models to assist in screening for low adherence are warranted." @default.
• W2122691108 created "2016-06-24" @default.
• W2122691108 creator A5019049183 @default.
• W2122691108 creator A5031165123 @default.
• W2122691108 creator A5033158091 @default.
• W2122691108 creator A5042154323 @default.
• W2122691108 creator A5056797758 @default.
• W2122691108 creator A5061735128 @default.
• W2122691108 creator A5085073979 @default.
• W2122691108 date "2009-06-01" @default.
• W2122691108 modified "2023-10-14" @default.
• W2122691108 title "Risk Factors for Poor Adherence to Eyedrops in Electronically Monitored Patients with Glaucoma" @default.
• W2122691108 cites W1534154425 @default.
• W2122691108 cites W1547375638 @default.
• W2122691108 cites W1895451668 @default.
• W2122691108 cites W1966279941 @default.
• W2122691108 cites W1968226582 @default.
• W2122691108 cites W1972110417 @default.
• W2122691108 cites W1973722314 @default.
• W2122691108 cites W1980641193 @default.
• W2122691108 cites W1982112616 @default.
• W2122691108 cites W1990286714 @default.
• W2122691108 cites W1994287577 @default.
• W2122691108 cites W1998207473 @default.
• W2122691108 cites W2005053663 @default.
• W2122691108 cites W2013506448 @default.
• W2122691108 cites W2015733557 @default.
• W2122691108 cites W2020555111 @default.
• W2122691108 cites W2040652295 @default.
• W2122691108 cites W2042394770 @default.
• W2122691108 cites W2051722503 @default.
• W2122691108 cites W2056317022 @default.
• W2122691108 cites W2068598411 @default.
• W2122691108 cites W2079471342 @default.
• W2122691108 cites W2091063199 @default.
• W2122691108 cites W2135469914 @default.
• W2122691108 cites W2145355470 @default.
• W2122691108 cites W2155227897 @default.
• W2122691108 cites W2155441883 @default.
• W2122691108 cites W2334366154 @default.
• W2122691108 cites W92460100 @default.
• W2122691108 doi "https://doi.org/10.1016/j.ophtha.2009.01.021" @default.
• W2122691108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19376591" @default.
• W2122691108 hasPublicationYear "2009" @default.
• W2122691108 type Work @default.
• W2122691108 sameAs 2122691108 @default.
• W2122691108 citedByCount "152" @default.
• W2122691108 countsByYear W21226911082012 @default.
• W2122691108 countsByYear W21226911082013 @default.
• W2122691108 countsByYear W21226911082014 @default.
• W2122691108 countsByYear W21226911082015 @default.
• W2122691108 countsByYear W21226911082016 @default.
• W2122691108 countsByYear W21226911082017 @default.
• W2122691108 countsByYear W21226911082018 @default.
• W2122691108 countsByYear W21226911082019 @default.
• W2122691108 countsByYear W21226911082020 @default.
• W2122691108 countsByYear W21226911082021 @default.
• W2122691108 countsByYear W21226911082022 @default.
• W2122691108 countsByYear W21226911082023 @default.
• W2122691108 crossrefType "journal-article" @default.
• W2122691108 hasAuthorship W2122691108A5019049183 @default.
• W2122691108 hasAuthorship W2122691108A5031165123 @default.
• W2122691108 hasAuthorship W2122691108A5033158091 @default.
• W2122691108 hasAuthorship W2122691108A5042154323 @default.
• W2122691108 hasAuthorship W2122691108A5056797758 @default.
• W2122691108 hasAuthorship W2122691108A5061735128 @default.
• W2122691108 hasAuthorship W2122691108A5085073979 @default.
• W2122691108 hasConcept C118487528 @default.
• W2122691108 hasConcept C126322002 @default.
• W2122691108 hasConcept C139719470 @default.
• W2122691108 hasConcept C141071460 @default.
• W2122691108 hasConcept C144024400 @default.
• W2122691108 hasConcept C144301174 @default.
• W2122691108 hasConcept C149923435 @default.
• W2122691108 hasConcept C162324750 @default.
• W2122691108 hasConcept C188816634 @default.
• W2122691108 hasConcept C23131810 @default.
• W2122691108 hasConcept C2776508836 @default.
• W2122691108 hasConcept C2776740260 @default.
• W2122691108 hasConcept C2776867660 @default.
• W2122691108 hasConcept C2777288759 @default.
• W2122691108 hasConcept C2778527774 @default.
• W2122691108 hasConcept C2780084366 @default.
• W2122691108 hasConcept C2780276452 @default.
• W2122691108 hasConcept C38180746 @default.
• W2122691108 hasConcept C71924100 @default.
• W2122691108 hasConcept C72563966 @default.
• W2122691108 hasConceptScore W2122691108C118487528 @default.
• W2122691108 hasConceptScore W2122691108C126322002 @default.
• W2122691108 hasConceptScore W2122691108C139719470 @default.
• W2122691108 hasConceptScore W2122691108C141071460 @default.
• W2122691108 hasConceptScore W2122691108C144024400 @default.
• W2122691108 hasConceptScore W2122691108C144301174 @default.
• W2122691108 hasConceptScore W2122691108C149923435 @default.
• W2122691108 hasConceptScore W2122691108C162324750 @default.
• W2122691108 hasConceptScore W2122691108C188816634 @default.
• W2122691108 hasConceptScore W2122691108C23131810 @default.
• W2122691108 hasConceptScore W2122691108C2776508836 @default.

• next